Gatti, Milo
Cojutti, Pier Giorgio
Bartoletti, Michele
Tonetti, Tommaso
Bianchini, Amedeo
Ramirez, Stefania
Pizzilli, Giacinto
Ambretti, Simone
Giannella, Maddalena
Mancini, Rita
Siniscalchi, Antonio
Viale, Pierluigi
Pea, Federico
Article History
Received: 17 March 2022
Accepted: 2 June 2022
First Online: 14 June 2022
Declarations
:
: The study was approved by the Ethical Committee of the IRCCS Azienda Ospedaliero-Universitaria in Bologna (No. 308/2021/Oss/AOUBo on 24 May 2021). Informed written consent was waived due to the retrospective and observational nature of the study.
: The patients included in case vignettes gave their informed consent for being included in the study.
: MG reports grants from Angelini S.p.A., outside the submitted work. F.P. reports personal fees from Angelini, Basilea Pharmaceutica, Gilead, Hikma, MSD, Pfizer, Sanofi-Aventis, Shionogi, Thermo Fisher, and Accelerate Diagnostics, outside the submitted work; has participated in speaker’s bureau for Accelerate Diagnostics, Angelini, Basilea Pharmaceutica, Gilead, Hikma, MSD, Pfizer, Sanofi-Aventis, Shionogi, Thermo Fisher, and as consultant for Angelini, Basilea Pharmaceutica, Gilead, MSD, Pfizer, Shionogi, outside the submitted work. P.V. has served as a consultant for bioMérieux, Gilead, Merck Sharp & Dohme, Nabriva, Nordic Pharma, Pfizer, Thermo-Fisher, and Venatorx, and received payment for serving on the speaker’s bureaus for Correvio, Gilead, Merck Sharp & Dohme, Nordic Pharma, and Pfizer, outside the submitted work. The other authors report no potential conflicts of interest for this work.